3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
4
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Erythroblastic, Acute
3
Prostatic Neoplasms
2
Mouth Neoplasms
2
Congenital Abnormalities
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Intraepithelial Lesions
1
Smoldering Multiple Myeloma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostate Adenocarcinoma
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Osteoporosis
1
Oropharyngeal Neoplasms
1
Obesity
1
Neurofibrosarcoma
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Melanoma
1
Malignant mesenchymal tumor
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Lung Neoplasms
1
Liposarcoma
1
Interventions
ofatumumab
10
Cyclophosphamide
6
fludarabine
5
ibrutinib
4
fludarabine phosphate
4
Bortezomib
3
Tablets
2
Chlorambucil
2
tirabrutinib
1
pegaspargase
1
nelarabine
1
immunotoxin HA22
1
bempegaldesleukin
1
Whole-Body Irradiation
1
Vincristine
1
Panobinostat
1
Observation
1
Nivolumab
1
Mitoxantrone
1
Methotrexate
1
Mesna
1
Mercaptopurine
1
Magnetic Resonance Imaging
1
MLN 8237
1
Lenalidomide
1
KW-2478
1
Hsp90 inhibitor KU757
1
Etoposide
1
Electrocardiography
1
Echocardiography
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Leukemia, B-Cell
×
Observation
×
Clear all
NCT01039376
2019-07-30
PROLONG
Novartis
Phase 3
Terminated
480 enrolled
30 charts